Subsequent Events	3 Months Ended
Sep. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 16 — SUBSEQUENT EVENTS The Company evaluated all events and transactions that occurred after September 30, 2024 up through the date the Company issued these consolidated financial statements, and unless disclosed below, there are not any material subsequent events that require disclosure in these consolidated financial statements. *Equity Transfer Agreement* On November 5, 2024, Sichuan Hupan Jincheng Enterprise Management Co., Ltd ("Sichuan Hupan"), a wholly owned subsidiary of Lakeside Holding Limited ("Lakeside") and a limited company incorporated in China, primarily in the business of pharmaceutical supply chain, entered into an equity transfer agreement (the "Equity Transfer Agreement") with Hubei Haoyaoshi Zhenghe Pharmacy Chain Co., Ltd and Hubei Huayao Pharmaceutical Co., Ltd to acquire 100% of the equity interests in Hupan Pharmaceutical (Hubei) Co., Ltd ("Hupan Pharmaceutical"), a comprehensive pharmaceutical distribution and supply chain service provider headquartered in Wuhan, China with verticals in brand promotion and healthcare technology support. Hubei Haoyaoshi Zhenghe Pharmacy Chain Co., Ltd and Hubei Huayao Pharmaceutical Co., Ltd. currently hold 90.0% and 10.0% of the equity interests in Hupan Pharmaceuticals, respectively. Pursuant to the Equity Transfer Agreement, Sichuan Hupan will acquire the entirety of the equity interests that Hubei Haoyaoshi Zhenghe Pharmacy Chain Co., Ltd and Hubei Huayao Pharmaceutical Co., Ltd. hold in Hupan Pharmaceutical, for a total consideration of RMB4.0 million (US$0.6 million), which will be paid in three installments. The first installment of RMB0.8 million (US$0.12 million) will be made in November 2024. As of this report date, the payment has not been made. The second installment of RMB2.4 million (US$0.36 million) shall be paid within 7 working days after the day on which the preconditions for equity transfer as set forth in Article 4 in the Equity Transfer Agreement hereof are fulfilled, and the Transferors confirm and promises in writing to the Transferee. The third installment of RMB0.8 million (US$0.12 million) shall be paid when the transfer is completed that the Parties have gone through all procedures such as company delivery and industrial and commercial registration of changes according to law.

Subsequent Events

3 Months Ended

Sep. 30, 2024

NOTE 16 — SUBSEQUENT EVENTS

The Company evaluated all events and transactions that occurred after September 30, 2024 up through the date the Company issued these consolidated financial statements, and unless disclosed below, there are not any material subsequent events that require disclosure in these consolidated financial statements.

Equity Transfer Agreement

On November 5, 2024, Sichuan Hupan Jincheng Enterprise Management Co., Ltd ("Sichuan Hupan"), a wholly owned subsidiary of Lakeside Holding Limited ("Lakeside") and a limited company incorporated in China, primarily in the business of pharmaceutical supply chain, entered into an equity transfer agreement (the "Equity Transfer Agreement") with Hubei Haoyaoshi Zhenghe Pharmacy Chain Co., Ltd and Hubei Huayao Pharmaceutical Co., Ltd to acquire 100% of the equity interests in Hupan Pharmaceutical (Hubei) Co., Ltd ("Hupan Pharmaceutical"), a comprehensive pharmaceutical distribution and supply chain service provider headquartered in Wuhan, China with verticals in brand promotion and healthcare technology support.

Hubei Haoyaoshi Zhenghe Pharmacy Chain Co., Ltd and Hubei Huayao Pharmaceutical Co., Ltd. currently hold 90.0% and 10.0% of the equity interests in Hupan Pharmaceuticals, respectively. Pursuant to the Equity Transfer Agreement, Sichuan Hupan will acquire the entirety of the equity interests that Hubei Haoyaoshi Zhenghe Pharmacy Chain Co., Ltd and Hubei Huayao Pharmaceutical Co., Ltd. hold in Hupan Pharmaceutical, for a total consideration of RMB4.0 million (US$0.6 million), which will be paid in three installments.

The first installment of RMB0.8 million (US$0.12 million) will be made in November 2024. As of this report date, the payment has not been made.

The second installment of RMB2.4 million (US$0.36 million) shall be paid within 7 working days after the day on which the preconditions for equity transfer as set forth in Article 4 in the Equity Transfer Agreement hereof are fulfilled, and the Transferors confirm and promises in writing to the Transferee.

The third installment of RMB0.8 million (US$0.12 million) shall be paid when the transfer is completed that the Parties have gone through all procedures such as company delivery and industrial and commercial registration of changes according to law.